Research has demonstrated that HDACis can downregulate the expression of the DNMT1 protein within the nucleus in human breast cancer cells [33], while inhibiting HDAC3 can increase the acetylation level of DNMT1, thereby decreasing its stability. Here, DNMT1 is linked to breast carcinoma.